SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors debating the stock's future amid intense technical volatility and mixed signals regarding its long-term growth versus aggressive share dilution. While some community members highlight its expanding backlog, acquisition strategy, and defense sector partnerships, others are concerned by repeated price pullbacks and are closely monitoring the company's ability to capitalize on its recent strategic positioning.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is currently trending as investors debate the impact of its manufacturing joint venture with Toyota, with the community split between those viewing the partnership as a scaling moat and those concerned by ongoing stock volatility and dilution. Bulls emphasize the firm's progress in FAA flight testing and infrastructure development, while bears continue to highlight high cash burn and the speculative nature of the eVTOL industry.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block Inc. is surging following a major restructuring plan that includes cutting 40% of its workforce as the company pivots toward an AI-native operational model. The community is actively debating the implications of using AI to drive margin expansion versus the potential long-term risks of mass layoffs and reduced human capital.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility and heavy volume as traders debate the company's pivot toward becoming an AI infrastructure backbone through its Private Connectivity Fabric and recent strategic acquisitions. While bulls point to massive hyperscaler deal potential and a critical fiber footprint as long-term catalysts, the stock faces intense selling pressure from institutional shorting and concerns regarding balance sheet constraints and legacy business decline.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio Inc. (NUVB) is drawing significant market attention as it transitions into a commercial-stage oncology company, with community focus centering on the commercial launch of its flagship drug, Ibtrozi, and strategic pipeline developments. Investors are actively debating the company's long-term valuation in light of recent financing moves and persistent buyout speculation, while closely monitoring how the firm's best-in-class pipeline candidates compete within the evolving oncology landscape.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum and volatility as investors react to positive FDA briefing documents regarding its mRNA flu vaccine candidate ahead of a key advisory committee vote. The community is actively debating the stock's long-term growth potential through its expanding oncology and rare disease pipeline, while also tracking high short interest that has fueled speculation of a potential short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors monitor the commercial launch of NEREUS for motion sickness and engage in active speculation regarding potential buyout interest from major pharmaceutical players. While the community remains focused on the company's pipeline developments and GLP-1 adjunct opportunities, ongoing discussions are fueled by frustration over persistent price volatility and the company's aggressive regulatory strategy.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is under significant pressure as investors navigate concerns over shifting consumer habits, the rise of GLP-1 weight-loss drugs, and softening same-store sales. While some traders view the stock as a defensive value play and an opportunity for long-term accumulation near key support levels, the broader community remains divided, with active discussions focusing on technical breakdown risks and the effectiveness of management's turnaround strategies.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing heightened investor volatility driven by intense competition from emerging prediction markets and ongoing debates over how these new event-based betting platforms impact its core sportsbook business. While community discourse remains polarized between long-term bulls highlighting robust revenue growth and record-breaking engagement and bearish traders concerned about institutional sell-offs and competitive threats, the stock is actively trending due to these conflicting narratives and shifting regulatory expectations.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic Inc. (SYM) is trending as investors aggressively rotate into Physical AI and robotics, driven by the sector's long-term potential as a critical infrastructure bottleneck. The community is actively debating the company's massive multi-billion dollar backlog and its strategic pivot toward high-margin software services against persistent concerns regarding customer concentration and execution pace.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision

Key PointsThe Chief Medical Officer of Mineralys Therapeutics reported selling 14,474 Common Stock shares across multiple transactions on June 15 and June 17, 2026, for a total value of approximately $350,000...

Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy

Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Rating of "Moderate Buy" by Brokerages

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rat...

Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday

Mineralys Therapeutics (NASDAQ:MLYS) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-mineralys-therapeutics-inc-stock...

Mineralys Therapeutics (NASDAQ:MLYS) Trading 8.2% Higher   - Should You Buy?

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 8.2% - Should You Buy...

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Jennison Associates LLC

Jennison Associates LLC grew its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 234.4% in the fourth quarter, according to its most recent filing with the...

Pictet Asset Management Holding SA Sells 76,286 Shares of Mineralys Therapeutics, Inc. $MLYS

Pictet Asset Management Holding SA trimmed its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 8.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 852,883 shares of the...

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's Why

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down - Here's What Happened...

Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 416 Shares of Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 416 shares of the business's stock in a transaction that occurred on Friday, April 17th. The shares were...

David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 416 shares of the stock in a transaction dated Friday, April 17th. The stock was sold at an average price...

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MLYSMineralys Therapeutics Inc

Latest MLYS News